Trial reportDiabetes2018
Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor Agonist.
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Diabetes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Effects of mirabegron on brown adipose tissue and metabolism in humans: A systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- Interventions associated with brown adipose tissue activation and the impact on energy expenditure and weight loss: A systematic review.Frontiers in endocrinology · 2022Pooled it
- Baseline serum metabolites predict fractures in individuals who were Black and had type 2 diabetes.Frontiers in endocrinology · 2026Trial
- Stimulation of the beta-2-adrenergic receptor with salbutamol activates human brown adipose tissue.Cell reports. Medicine · 2023Trial
- The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men.Diabetes, obesity & metabolism · 2020Trial
- Metabolomic effects of androgen deprivation therapy treatment for prostate cancer.Cancer medicine · 2020Trial
- The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans.The Journal of clinical investigation · 2020Trial
- Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.The Journal of clinical investigation · 2020Trial
- The conjugation-resistant bile acid norUDCA cures liver fibrosis but impairs systemic energy metabolism.Molecular metabolism · 2026Article
- Hepatic protein kinase Cβ antagonizing p38American journal of physiology. Gastrointestinal and liver physiology · 2025Article
- Phase Ia/b Multicenter Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients.Cancer research communications · 2025Article
- Mirabegron treatment reduces myofibroblasts and CXCR2 expression in adipose tissue in obesity.Molecular medicine (Cambridge, Mass.) · 2025Article
- Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Targeting Dlat-Trpv3 pathway by hyperforin elicits non-canonical promotion of adipose thermogenesis as an effective anti-obesity strategy.Journal of advanced research · 2025Article
- Arctiin, a lignan compound, enhances adipose tissue browning and energy expenditure by activating the adenosine AMolecular medicine (Cambridge, Mass.) · 2025Article
- Obesity: pathophysiology and therapeutic interventions.Molecular biomedicine · 2025Review
- Bile acid metabolism in type 2 diabetes mellitus.Nature reviews. Endocrinology · 2025Review
- G-Protein-Coupled Receptor (GPCR) Signaling and Pharmacology in Metabolism: Physiology, Mechanisms, and Therapeutic Potential.Biomolecules · 2025Review
- Brown Fat and Metabolic Health: The Diverse Functions of Dietary Components.Endocrinology and metabolism (Seoul, Korea) · 2024Review
- Physiological and metabolic functions of the βJournal of physiology and biochemistry · 2024Review
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 1 institution in 1 country.
Alison S BaskinDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Joyce D LindermanDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Robert J BrychtaDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Suzanne McGeheeDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Esti Anflick-ChamesDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Cheryl CeroDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
James W JohnsonDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Alana E O'MaraDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Laura A FletcherDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Brooks P LeitnerDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Courtney J DuckworthDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Shan HuangDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Hongyi CaiClinical Mass Spectrometry Core, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
H Martin GarraffoClinical Mass Spectrometry Core, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Corina M MilloDepartment of Positron Emission Tomography, National Institutes of Health, Bethesda, MD.
William DieckmannDepartment of Positron Emission Tomography, National Institutes of Health, Bethesda, MD.
Vladimir TolstikovBERG, Framingham, MA.
Emily Y ChenBERG, Framingham, MA.
Fei GaoBERG, Framingham, MA.
Niven R NarainBERG, Framingham, MA.
Michael A KiebishBERG, Framingham, MA.
Peter J WalterClinical Mass Spectrometry Core, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Peter HerscovitchDepartment of Positron Emission Tomography, National Institutes of Health, Bethesda, MD.
Kong Y ChenDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Aaron M CypessDiabetes, Endocrinology, and Obesity Branch, Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD aaron.cypess@nih.gov.ORCID 0000-0002-5570-9346
National Institutes of Health · US
Funding
Clinical Mass Spectrometry CoreZICDK075039 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$3.3MHuman Energy and Body Weight Regulation CoreZICDK071013 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$1.8MDevelopment of obesity and metabolic clinical research programsZIADK071014 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$1.8MPhysiological Responses to Activation of Human Brown Adipose TissueZIADK075116 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$734kThe Molecular, Cellular, and Genetic characterization of Human Adipose Tissue and its Role in MetabolismZIADK075112 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$440kMechanisms Underlying Adipose Tissue ThermogenesisZIADK075115 · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2025 to 2025
$294kHTS for Detection of deltaF508 CFTR at the Cell SurfaceR01DK071013 · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · 2005 to 2005
$256kNIDDK NIH HHS R01 DK071013NIDDK NIH HHS R01 DK071014NIDDK NIH HHS R01 DK075112
Abstract
β3-adrenergic receptor (AR) agonists are approved to treat only overactive bladder. However, rodent studies suggest that these drugs could have other beneficial effects on human metabolism. We performed tissue receptor profiling and showed that the human β3-AR mRNA is also highly expressed in gallbladder and brown adipose tissue (BAT). We next studied the clinical implications of this distribution in 12 healthy men given one-time randomized doses of placebo, the approved dose of 50 mg, and 200 mg of the β3-AR agonist mirabegron. There was a more-than-dose-proportional increase in BAT metabolic activity as measured by [
Indexed as
AcetanilidesAdipose Tissue, BrownAdolescentAdrenergic beta-AgonistsAdultAgedAged, 80 and overAnimalsBile Acids and SaltsGallbladderHealthy VolunteersHumansMiceMice, Inbred C57BLMiddle AgedReceptors, Adrenergic, betaAcetanilidesAdrenergic beta-AgonistsBile Acids and SaltsmirabegronReceptors, Adrenergic, betaReceptors, Adrenergic, beta-3RNA, MessengerThiazoles
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.